Journal of Vascular and Interventional Radiology
Volume 17, Issue 9 , Pages 1425-1439 , September 2006

Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies: Part 2: Special Topics

  • Riad Salem, MD, MBA

      Affiliations

    • Department of Radiology, Kanata, Canada
    • Corresponding Author InformationAddress correspondence to R.S.
    • ,
  • Kenneth G. Thurston, MA

      Affiliations

    • Department of Robert H. Lurie Comprehensive Cancer Center, 676 North St Clair, Suite 800, Chicago, Illinois 60611; and MDS Nordion, Kanata, Canada

Received 25 June 2006 ,Revised 26 June 2006 ,Accepted 26 June 2006.

References 

  1. Salem R , Thurston KG . Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies . Part 1: technical and methodologic considerations J Vasc Interv Radiol . 2006;17:1251–1278
  2. Bruix J , Llovet JM , Castells A , et al.   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution . Hepatology . 1998;27:1578–1583
  3. Lin DY , Liaw YF , Lee TY , et al.   Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial . Gastroenterology . 1988;94:453–456
  4. Pelletier G , Roche A , Ink O , et al.   A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma . J Hepatol . 1990;11:181–184
  5. Madden MV , Krige JE , Bailey S , et al.   Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma . Gut . 1993;34:1598–1600
  6. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire . A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma . N Engl J Med . 1995;332:1256–1261
  7. Llovet JM , Real MI , Montana X , et al.   Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial . Lancet . 2002;359:1734–1739
  8. Lo CM , Ngan H , Tso WK , et al.   Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma . Hepatology . 2002;35:1164–1171
  9. Kato T , Nemoto R , Mori H , et al.   Arterial chemoembolization with microencapsulated anticancer drug: an approach to selective cancer chemotherapy with sustained effects . JAMA . 1981;245:1123–1127
  10. Llovet JM , Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival . Hepatology . 2003;37:429–442
  11. Carr BI . Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients . Liver Transpl . 2004;10(2 suppl 1):S107–S110
  12. Salem R , Lewandowski RJ , Atassi B , et al.   Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival . J Vasc Interv Radiol . 2005;16:1627–1639
  13. Kulik LM , Mulcahy MF , Hunter RD , et al.   Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report . Liver Transpl . 2005;11:1127–1131
  14. Kulik L, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (Thera-Sphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RF ablation and bridge to transplantation. J Surg Oncol 2006 (in press).
  15. Lau WY , Ho S , Leung TW , et al.   Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres . Int J Radiat Oncol Biol Phys . 1998;40:583–592
  16. Tellez C , Benson AB , Lyster MT , et al.   Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature . Cancer . 1998;82:1250–1259
  17. Talamonti MS , Tellez C , Benson AB . Local-regional therapy for metastatic liver tumors . Cancer Treat Res . 1998;98:172–199
  18. Salman HS , Cynamon J , Jagust M , et al.   Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver . Clin Colorectal Cancer . 2002;2:173–179
  19. Lang EK , Brown CL . Colorectal metastases to the liver: selective chemoembolization . Radiology . 1993;189:417–422
  20. Gupta S , Johnson MM , Murthy R , et al.   Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival . Cancer . 2005;104:1590–1602
  21. Sarfaraz M , Kennedy AS , Cao ZJ , et al.   Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors . Med Phys . 2003;30:199–203
  22. Dhabuwala A , Lamerton P , Stubbs RS . Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT) . BMC Nucl Med . 2005;5:7
  23. Ho S , Lau WY , Leung TW , et al.   Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin . Br J Radiol . 1997;70:823–828
  24. Yip D , Allen R , Ashton C , et al.   Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer . J Gastroenterol Hepatol . 2004;19:347–349
  25. Ingold JA , Reed GB , Kaplan HS , et al.   Radiation hepatitis . AJR Radium Ther Nucl Med . 1965;93:200–208
  26. Ho S , Lau WY , Leung TW , et al.   Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours . Eur J Nucl Med . 1996;23:947–952
  27. Thamboo T , Tan KB , Wang SC , et al.   Extra-hepatic embolisation of Y-90 microspheres from selective internal radiation therapy (SIRT) of the liver . Pathology . 2003;35:351–353
  28. Goin JE , Dancey JE , Roberts CA , et al.   Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemoembolization versus yttrium-90 glass microspheres . World J Nucl Med . 2004;3:49–56
  29. Steel J , Baum A , Carr B . Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (Therasphere) . Psychooncology . 2004;13:73–79
  30. Sato KT, Omary RA, Ryu R, et al. Radioembolization with yttrium-90 microspheres: angiographic and technical considerations. Tech Vasc Interv Radiol 2006 (in press).
  31. Murthy R , Xiong H , Nunez R , et al.   Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results . J Vasc Interv Radiol . 2005;16:937–945
  32. Murthy R , Nunez R , Szklaruk J , et al.   Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications . Radiographics . 2005;25(suppl 1):S41–S55
  33. Kennedy AS , Coldwell D , Nutting C , et al.   Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience . Int J Radiat Oncol Biol Phys . 2006;65:412–425
  34. Liu DM , Salem R , Bui JT , et al.   Angiographic considerations in patients undergoing liver-directed therapy . J Vasc Interv Radiol . 2005;16:911–935
  35. SIR-Spheres Yttrium-90 microspheres [package insert] . Lane Cove, Australia: SIRTeX Medical; 2004;
  36. Sirtex Medical Training Manual . Lane Cove, Australia: SIRTeX Medical; 2005;
  37. Ho S , Lau WY , Leung TW , et al.   Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer . Eur J Nucl Med . 1997;24:293–298
  38. Dawson LA , Normolle D , Balter JM , et al.   Analysis of radiation-induced liver disease using the Lyman NTCP model . Int J Radiat Oncol Biol Phys . 2002;53(4):810–821
  39. Yorke ED , Jackson A , Fox RA , et al.   Can current models explain the lack of liver complications in Y-90 microsphere therapy? . Clin Cancer Res . 1999;5(10 suppl):3024s–3030s
  40. Cheng JC , Wu JK , Huang CM , et al.   Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description . Radiother Oncol . 2002;63:41–45
  41. Nakakubo Y , Kondo S , Katoh H , et al.   Biliary stricture as a possible late complication of radiation therapy . Hepatogastroenterology . 2000;47:1531–1532
  42. Cherqui D , Palazzo L , Piedbois P , et al.   Common bile duct stricture as a late complication of upper abdominal radiotherapy . J Hepatol . 1994;20:693–697
  43. Lewandowski R , Salem R . Incidence of radiation cholecystitis in patients receiving Y-90 treatment for unresectable liver malignancies . J Vasc Interv Radiol . 2004;15(suppl):S162
  44. Ayav A , Habib N , Jiao LR . Portal hypertension secondary to 90Yttrium microspheres: an unknown complication . J Clin Oncol . 2005;23:8275–8276
  45. Rubbia-Brandt L , Audard V , Sartoretti P , et al.   Severe hepatic sinusoidal obstruction associated with oxaliplatinbased chemotherapy in patients with metastatic colorectal cancer . Ann Oncol . 2004;15:460–466
  46. Vauthey JN , Pawlik TM , Ribero D , et al.   Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases . J Clin Oncol . 2006;24:2065–2072
  47. Brock H , Gunther RW , Haage P . Liver cirrhosis as sequela of selective hepatic radio-embolization with Yttrium (Y-90) microspheres . Rofo . 2006;178:546–548
  48. Marn CS , Andrews JC , Francis IR , et al.   Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings . Radiology . 1993;187:125–128
  49. Salem R . Idiosyncratic reactions following Y90 treatment . Chicago: Northwestern Memorial Hospital; 2006;
  50. Sato K , Lewandowski RJ , Bui JT , et al.   Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization . Cardiovasc Intervent Radiol . 2006;29:522–529
  51. Gray BN . Use of SIR-Spheres in patients with impaired liver function: safety notice . Lane Cove, Australia: SIRTeX Medical; 2003;
  52. Goin JE , Salem R , Carr BI , et al.   Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis . J Vasc Interv Radiol . 2005;16:195–203
  53. Goin JE , Salem R , Carr BI , et al.   Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities . J Vasc Interv Radiol . 2005;16:205–213
  54. TheraSphere yttrium-90 microspheres [package insert] . Kanata, ON, Canada: MDS Nordion; 2004;
  55. Andrews JC , Walker SC , Ackermann RJ , et al.   Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up . J Nucl Med . 1994;35:1637–1644
  56. Herba MJ , Thirlwell MP . Radioembolization for hepatic metastases . Semin Oncol . 2002;29:152–159
  57. Rhee TK , Omary RA , Gates V , et al.   The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma . J Vasc Interv Radiol . 2005;16:1085–1091
  58. Wang S, Ho YY, Leung F, et al. Outcomes following selective internal with SIR-Spheres in non-resectable hepatic malignancy. World Conference on Interventional Oncology; June 12–16, 2006. Cernobbio, Italy.
  59. Nutting C, Coldwell D, Kennedy AK. Coil embolization prevents GI ulcers during yttrium-90 hepatic radioembolization. Presented at the Society of Interventional Radiology Annual Meeting March 25–30, 2004; Phoenix, Ariz.
  60. Charnsangavej C . Chemoembolization of liver tumors . Semin Invest Radiol . 1993;10:150–160
  61. Belli L , Magistretti G , Puricelli GP , et al.   Arteritis following intra-arterial chemotherapy for liver tumors . Eur Radiol . 1997;7:323–326
  62. Gray B , Van Hazel G , Hope M , et al.   Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer . Ann Oncol . 2001;12:1711–1720
  63. Van Hazel G , Blackwell A , Anderson J , et al.   Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer . J Surg Oncol . 2004;88:78–85
  64. Van Hazel G, Price D, Bower G, et al. Selective internal radiation therapy (SIRT) for liver metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: a phase I/II dose escalation study. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium January 27–29, 2005. Hollywood, Fla.
  65. Goldstein D, Van Hazel G, Pavlakis N, et al. Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan: a phase I dose escalation study. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium January 27–29, 2005. Hollywood, Fla. Abstract #108.
  66. Van Hazel G, Price D, Bower G, et al. Selective internal radiation therapy (SIRT) plus systemic chemotherapy with FOLFOX4: a phase I dose escalation study. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium January 27–29,2005. Hollywood, Fla. Abstract #265.
  67. Stubbs RS , Cannan RJ , Mitchell AW . Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases . Hepatogastroenterology . 2001;48:333–337
  68. Stubbs RS , Cannan RJ , Mitchell AW . Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases . J Gastrointest Surg . 2001;5:294–302
  69. Sharma RA, Van Hazel GA, Blanshard K, et al. Internal radiation treatment of liver metastases from colorectal cancer with concomitant systemic radiosensitising chemotherapy. Presented at the World Congress on Gastrointestinal Cancer; June 28 through July 1, 2006; Barcelona, Spain.
  70. Lewandowski RJ , Thurston KG , Goin JE , et al.   90Y microsphere (Therasphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging . J Vasc Interv Radiol . 2005;16:1641–1651
  71. Coldwell D, Nutting C, Kennedy AK. Use of Yttrium-90 SirSpheres to treat metastatic unresectable neuroendorcine tumors to the liver. World Congress on Gastrointestinal Cancer; June 28 through July 1, 2006; Barcelona, Spain.
  72. Kennedy A, Coldwell D, Nutting C, et al. Hepatic brachytherapy for GI neuroendocrine tumors with Y90 microspheres: long-term USA results. International Conference on Advanced Communication Technology July 11–15, 2005. Paris, France.
  73. O'Toole D , Ruszniewski P . Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours . Best Pract Res Clin Gastroenterol . 2005;19:585–594
  74. Atwell TD , Charboneau JW , Que FG , et al.   Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques . Cardiovasc Intervent Radiol . 2005;28:409–421
  75. Touzios JG , Kiely JM , Pitt SC , et al.   Neuroendocrine hepatic metastases: does aggressive management improve survival? . Ann Surg . 2005;241:776–783
  76. Hertl M , Cosimi AB . Liver transplantation for malignancy . Oncologist . 2005;10:269–281
  77. de Herder WW , Krenning EP , Van Eijck CH , et al.   Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas . Endocr Relat Cancer . 2004;11:19–34
  78. Stuart K . Chemoembolization in the management of liver tumors . Oncologist . 2003;8:425–437
  79. Panzuto F , Nasoni S , Delle Fave G . Medical treatment of digestive neuroendocrine tumours . Minerva Endocrinol . 2001;26:145–148
  80. Proye C . Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization . World J Surg . 2001;25:685–688
  81. Murthy R, Xiong H, Eng C, et al. Yttrium-90 microsphere liver-directed therapy in patients with metastatic colorectal cancer following failure with cetuximab and bevacizumab. World Conference on Interventional Oncology 2006. Cernobbio, Italy.
  82. Carpanese L, Pizzi G, Golfieri R, Fiore F, et al. A phase II clinical trial on hepatic intra-arterial injection of Yttrium-90 microspheres in unresectable colorectal liver metastases refractory to standard IV chemotherapy: preliminary results. World Conference on Interventional Oncology; June 12–16, 2006; Cernobbio, Italy.
  83. Kim DY , Kwon DS , Salem R , et al.   Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation . J Gastrointest Surg . 2006;10:413–416
  84. Kim W , Clark TW , Baum RA , et al.   Risk factors for liver abscess formation after hepatic chemoembolization . J Vasc Interv Radiol . 2001;12:965–968
  85. Thomas KT , Bream PR , Berlin J , et al.   Use of percutaneous drainage to treat hepatic abscess after radiofrequency ablation of metastatic pancreatic adenocarcinoma . Am Surg . 2004;70:496–499
  86. Geschwind JF , Kaushik S , Ramsey DE , et al.   Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors . J Vasc Interv Radiol . 2002;13:1163–1166
  87. Lau GBH, Wang SC, Ho YY. Technical aspects in the workup for yttrium-90 SIR-Spheres radioembolo-therapy in the treatment of hepatic tumors. World Conference on Interventional Oncology; June 12–16, 2006; Cernobbio, Italy.
  88. Lewandowski R, Salem R, Thurston K, et al. Radiation segmentectomy of unresectable of liver carcinoma using selective infusion of intraarterial yttrium-90 TheraSphere. Radiological Society of North America; November 28 through December 3, 2004; Chicago.
  89. Breedis C , Young G . The blood supply of neoplasms in the liver . Am J Pathol . 1954;30:969–977
  90. Lin G , Lunderquist A , Hagerstrand I , et al.   Postmortem examination of the blood supply and vascular pattern of small liver metastases in man . Surgery . 1984;96:517–526
  91. Bierman HR , Byron RL , Kelley KH , et al.   Studies on the blood supply of tumors in man. III: vascular patterns of the liver by hepatic arteriography in vivo . J Natl Cancer Inst . 1951;12:107–131
  92. Russell JL , Carden JL , Herron HL . Dosimetry calculations for yttrium-90 used in the treatment of liver cancer . Endocuriether Hyperthermia Oncol . 1988;4:171–186
  93. Campbell AM , Bailey IH , Burton MA . Analysis of the distribution of intraarterial microspheres in human liver following hepatic yttrium-90 microsphere therapy . Phys Med Biol . 2000;45:1023–1033
  94. Campbell AM , Bailey IH , Burton MA . Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy . Phys Med Biol . 2001;46:487–498
  95. Zavgorodni SF . A model for dose estimation in therapy of liver with intraarterial microspheres . Phys Med Biol . 1996;41:2463–2480
  96. Gray BN , Burton MA , Kelleher D , et al.   Tolerance of the liver to the effects of yttrium-90 radiation . Int J Radiat Oncol Biol Phys . 1990;18:619–623
  97. Salem R , Thurston KG , Carr BI , et al.   Yttrium-90 microspheres: radiation therapy for unresectable liver cancer . J Vasc Interv Radiol. . 2002;13(suppl):S223–S229
  98. Snyder W , Ford M , Warner G , et al.   Absorbed dose per unit cumulated activity for selected radionuclides and organs . New York: Society of Nuclear Medicine; 1975–1976;
  99. Sarfaraz M , Kennedy AS , Lodge MA , et al.   Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma . Med Phys . 2004;31:2449–2453
  100. Lau WY , Leung WT , Ho S , et al.   Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study . Br J Cancer . 1994;70:994–999
  101. Leung TW , Lau WY , Ho SK , et al.   Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors . Int J Radiat Oncol Biol Phys . 1995;33:919–924
  102. Brown KT . Fatal pulmonary complications after arterial embolization with 40-120-micro m tris-acryl gelatin microspheres . J Vasc Interv Radiol . 2004;15:197–200
  103. Murata S , Tajima H , Abe Y , et al.   Temporary occlusion of two hepatic veins for chemoembolization of hepatocellular carcinoma with arteriohepatic vein shunts . AJR Am J Roentgenol . 2005;184:415–417
  104. Chung JW , Park JH , Han JK , et al.   Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization . Radiology . 1996;198:33–40
  105. Charnsangavej C , Carrasco CH , Wallace S , et al.   Hepatic arterial flow distribution with hepatic neoplasms: significance in infusion chemotherapy . Radiology . 1987;165:71–73
  106. Leung DA , Goin JE , Sickles C , et al.   Determinants of postembolization syndrome after hepatic chemoembolization . J Vasc Interv Radiol . 2001;12:321–326
  107. Georgiades CS , Hong K , D'Angelo M , et al.   Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis . J Vasc Interv Radiol . 2005;16:1653–1659
  108. Chung JW , Park JH , Han JK , et al.   Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization . AJR Am J Roentgenol . 1995;165:315–321
  109. Katsumori T , Fujita M , Takahashi T , et al.   Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein . Cardiovasc Intervent Radiol . 1995;18:217–221
  110. Salem R , Lewandowski R , Roberts C , et al.   Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis . J Vasc Interv Radiol . 2004;15:335–345
  111. Lewandowski R, Alli A, Atassi B, et al. Retraction of portal vein thrombus following treatment with Y90 TheraSphere: a secondary sign of tumor response. Presented at the Society of Interventional Radiology Annual Meeting; March 30 through April 4, 2006; Toronto, ON, Canada.
  112. Wong CY , Qing F , Savin M , et al.   Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging . J Vasc Interv Radiol . 2005;16:1101–1106
  113. Wong CY , Salem R , Qing F , et al.   Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET . J Nucl Med . 2004;45:1892–1897
  114. Wong CY , Salem R , Raman S , et al.   Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI . Eur J Nucl Med Mol Imaging . 2002;29:815–820
  115. Therasse P , Arbuck SG , Eisenhauer EA , et al.   New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada . J Natl Cancer Inst . 2000;92:205–216
  116. Bruix J , Sherman M , Llovet JM , et al.   Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver . J Hepatol . 2001;35:421–430
  117. Bienert M , McCook B , Carr BI , et al.   Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases . Eur J Nucl Med Mol Imaging . 2005;32:723
  118. Bienert M , McCook B , Carr BI , et al.   90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT . Eur J Nucl Med Mol Imaging . 2005;32:778–787
  119. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MRI for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006; 17 (in press).
  120. Wickremesekera JK , Chen W , Cannan RJ , et al.   Serum proinflammatory cytokine response in patients with advanced liver tumors following selective internal radiation therapy (SIRT) with (90)Yttrium microspheres . Int J Radiat Oncol Biol Phys . 2001;49:1015–1021
  121. Goldberg SN , Grassi CJ , Cardella JF , et al.   Image-guided tumor ablation: standardization of terminology and reporting criteria . J Vasc Interv Radiol . 2005;16:765–778

 R.S. is a consultant for MDS Nordion (Kanata, ON, Canada) and has lectured for Sirtex Medical (Lane Cove, Australia). K.G.T. is Director of Clinical Affairs for MDS Nordion. No research support was provided for this manuscript, and neither manufacturer had any input in this document.

PII: S1051-0443(07)60924-5

doi: 10.1097/01.RVI.0000235779.88652.53

Journal of Vascular and Interventional Radiology
Volume 17, Issue 9 , Pages 1425-1439 , September 2006

Article Tools